Condition
Cerebral Arteriovenous Malformations
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed2
Recruiting2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07103304Not Yet RecruitingPrimary
Liquid Biopsies for Detecting Somatic Mutations in Sporadic Cerebral Arteriovenous Malformations.
NCT03676868RecruitingPrimary
Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations
NCT06259292Recruiting
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
NCT02180958CompletedPrimary
Evaluation of ONYX in ENDOVASCULAR Treatment of Cerebral AVMs
NCT02602990CompletedPrimary
Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent
Showing all 5 trials